We are live on ! Find out more
TRIB

Trinity Biotech
TRIB

92 hedge funds and large institutions have $323M invested in Trinity Biotech in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

10% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 30

6% more capital invested

Capital invested by funds: $303M → $323M (+$19.3M)

3% more funds holding

Funds holding: 89 → 92 (+3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

38% less call options, than puts

Call options by funds: $287K | Put options by funds: $466K

Holders
92
Holders Change
+3
Holders Change %
+3.37%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
9
Increased
33
Reduced
30
Closed
6
Calls
$287K
Puts
$466K
Net Calls
-$179K
Net Calls Change
+$437K

Top Buyers

Rank Fund Capital Flow
1
JHIU
Janus Henderson Investors US
Colorado
+$9.09M
2
SM
Senvest Management
New York
+$7.95M
3
Boston Partners
Boston Partners
Massachusetts
+$5.16M
4
DM
Deerfield Management
New York
+$4.55M
5
RFC
Russell Frank Company
Washington
+$4.03M

Top Sellers

Rank Fund Capital Flow
1
LSC
Lyon Street Capital
California
-$6.87M
2
Millennium Management
Millennium Management
New York
-$5.51M
3
GIP
Granite Investment Partners
California
-$1.24M
4
KCM
Keane Capital Management
North Carolina
-$937K
5
Citadel Advisors
Citadel Advisors
Florida
-$892K
Name Holding Trade Value Shares
Change 		Change in
Stake
UIC
26
Uniplan Investment Counsel
Wisconsin
$4.58M +$4.39M +50,681 New
TCM
27
Tygh Capital Management
Oregon
$4.18M +$276K +3,184 +7%
Allianz Asset Management
28
Allianz Asset Management
Germany
$3.99M -$54K -624 -1%
SC
29
Skylands Capital
Wisconsin
$3.94M -$63.2K -730 -2%
KB
30
Kimelman & Baird
New York
$3.82M +$569K +6,569 +18%
GA
31
Geneva Advisors
Illinois
$3.25M +$437K +5,047 +16%
LSC
32
Lyon Street Capital
California
$3.13M -$6.87M -79,385 -70%
DGHMC
33
Dalton, Greiner, Hartman, Maher & Co
New York
$2.65M +$34.1K +394 +1%
TA
34
Teton Advisors
New York
$2.47M – – –
RHJA
35
Rice Hall James & Associates
California
$2.38M -$22.1K -255 -1%
SKK
36
Shepherd Kaplan Krochuk
Massachusetts
$2.27M -$103K -1,185 -5%
CCP
37
Centaur Capital Partners
Texas
$2.17M -$260K -3,000 -11%
BCA
38
Benchmark Capital Advisors
New York
$1.67M – – –
Two Sigma Investments
39
Two Sigma Investments
New York
$1.51M +$723K +8,354 +99%
GF
40
Gabelli Funds
New York
$1.44M – – –
US Bancorp
41
US Bancorp
Minnesota
$1.29M +$318K +3,674 +35%
WIC
42
Woodmont Investment Counsel
Tennessee
$1.12M – – –
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.06M +$1.99K +23 +0.2%
Arrowstreet Capital
44
Arrowstreet Capital
Massachusetts
$1.02M -$256K -2,960 -21%
Asset Management One
45
Asset Management One
Japan
$948K +$197K +2,280 +28%
AAP
46
Ardsley Advisory Partners
Connecticut
$948K +$303K +3,500 +50%
Millennium Management
47
Millennium Management
New York
$907K -$5.51M -63,604 -86%
PI
48
Putnam Investments
Massachusetts
$903K -$7.1K -82 -0.8%
Deutsche Bank
49
Deutsche Bank
Germany
$890K +$425K +4,910 +99%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$889K +$447K +5,160 +110%
1
2
3 4

TRIB Hedge Fund Activity: Q2 2015 in Review

92 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2015, worth a combined $323M — up 6.4% from $303M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TRIB positions and 6 closed out — a net gain of 3 holders — while 33 added to existing stakes and 30 trimmed.

The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $9.09M. The largest seller was Lyon Street Capital, cutting an estimated $6.87M.

  • 92 institutional investors held Trinity Biotech (TRIB) as of Q2 2015, up from 89 in Q1 2015.
  • Funds reported $323M of Trinity Biotech stock for Q2 2015, up 6.4% quarter-over-quarter.
  • 9 funds opened new Trinity Biotech positions in Q2 2015 and 6 closed out, a net change of +3 holders.
  • The largest Trinity Biotech buyer in Q2 2015 was Janus Henderson Investors US, an estimated $9.09M added.
  • The largest Trinity Biotech seller in Q2 2015 was Lyon Street Capital, an estimated $6.87M sold.

Based on aggregated 13F filings for Q2 2015.